Amoxycillin as sodium salt mg, clavulanic acid as potassium clavulanate mg. For reconstitution as augmentin and treatment regimen intravenous injection or infusion.
How to identify the Product: Sterile powder for injection in vial. Resistance to many antibiotics is caused by bacterial enzymes which destroy the antibiotic before it can act on the pathogen. Clavulanate by itself has little antibacterial activity; augmentin and treatment regimen, in association with amoxycillin as Augmentin, it produces an antibiotic agent of augmentin and treatment regimen spectrum with wide application in hospital and general practice.
Augmentin is bactericidal to a wide range of organisms including:. The pharmacokinetics of the two components of Augmentin are closely matched. Doubling the dosge of Augmentin approximately doubles the serum levels achieved.
Augmentin is an antibiotic agent with a notably broad spectrum of activity against the commonly occurring bacterial pathogens in general practice and hospital. The beta-lactamase inhibitory action of clavulanate cabin and cottage plans the spectrum of amoxycillin to embrace a wider range of organisms, including many resistant to other beta-lactam antibiotics. Augmentin Intravenous is indicated for short-term treatment of bacterial infections at the following sites when amoxycillin-resistant beta-lactamase-producing strains are suspected as the cause.
In other situations, amoxycillin alone should be considered. Lower Respiratory Tract Infections in particular acute exacerbation of chronic bronchitis especially if considered severebronchopneumonia.
Genito-urinary Tract and Abdominal Infections in particular cystitis especially when recurrent or complicated - excluding prostatitisseptic abortion, pelvic or puerperal sepsis and intra-abdominal sepsis.
Skin and Soft Tissue Infections in particular cellulitis, diverticulitis and accutane bites and severe dental abscess with spreading cellulitis.
Prophylaxis of wound infection associated with surgical procedures in particular gastro-intestinal, pelvic, major head and neck surgery and after limb amputation for infection. A comprehensive list of sensitive organisms is provided in Pharmacological properties section. Mixed infections caused by amoxycillin-susceptible organisms in conjunction with Augmentin-susceptible beta-lactamase-producing organisms may be treated with Augmentin.
These infections should not require the addition of another antibiotic resistant to beta-lactamase. Attention should be paid to possible cross-sensitivity with other beta-lactam antibiotics, e. Changes in liver function tests have been observed in some patients receiving co-amoxiclav. The clinical significance of these changes is uncertain but co-amoxiclav should be used with caution in patients with evidence of hepatic dysfunction.
Cholestatic jaundice, augmentin and treatment regimen, which may be severe, but is usually reversible, has been reported rarely. Signs and symptoms may not become apparent for several weeks after treatment has ceased. Serious and occasionally fatal hypersensitivity anaphylactoid reactions have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity see "Contra-indications". Erythematous rashes have been associated with glandular fever in patients receiving amoxycillin.
Prolonged use may also occasionally result in overgrowth of non-susceptible augmentin and treatment regimen. During the administration of high doses constipation and lidocaine hydrochloride jelly Augmentin adequate fluid intake and urinary output should be maintained to augmentin and treatment regimen the possibility of crystalluria.
When present in high concentrations in urine at room temperature, amoxycillin may precipitate in bladder catheters. A regular check on patency should be maintained. Reproduction studies in animals mice and rats with orally and parenterally administered co-amoxiclav have shown no teratogenic effects.
There is limited experience of the use of co-amoxiclav in human pregnancy. As with all medicines, use should be avoided in pregnancy, especially during the first trimester, unless considered essential by the physician. Co-amoxiclav may be administered during the period of lactation. With the exception of the risk of sensitisation, augmentin and treatment regimen, associated with the excretion of trace quantities in breast milk, there are no known detrimental effects for the breast-fed infant.
Adverse effects on the ability to drive or operate machinery have not been observed. Augmentin Intravenous should not be mixed with blood products, other proteinaceous fluids such as protein hydrolysates or with intravenous lipid emulsions. If Augmentin is prescribed concurrently with an aminoglycoside, the antibiotics should not be mixed in the syringe, intravenous fluid container or giving set because loss of activity of the aminoglycoside can occur under these conditions.
Prolongation of bleeding time and prothrombin time have been reported in some patients receiving co-amoxiclav. Co-amoxiclav should be used with care in patients on anticoagulant therapy. In common with other broad-spectrum antibiotics, co-amoxiclav may reduce the efficacy of oral contraceptives and patients should be warned accordingly. Concomitant use of allopurinol during treatment with amoxycillin can increase the likelihood of allergic skin reactions. There are no data on the concomitant use of co-amoxiclav and allopurinol.
Diarrhoea, indigestion, nausea, augmentin and treatment regimen, vomiting, and mucocutaneous candidiasis have been reported. Antibiotic-associated colitis including pseudomembranous colitis and haemorrhagic colitis has been reported rarely. Nausea, although uncommon, is more often associated with higher oral dosages. If GI side effects occur with oral therapy they may be reduced by taking co-amoxiclav at the start of meals.
Superficial tooth discoloration has carcinogens and breast cancer reported rarely, mostly with the suspension. It can usually be removed by brushing, augmentin and treatment regimen.
Hepatitis and cholestatic jaundice have been reported rarely. These hepatic reactions have been reported more commonly with co-amoxiclav than with other penicillins.
After Augmentin hepatic reactions have been reported more frequently in males and elderly patients, particularly those over 65 years. The risk increases with duration of treatment longer than 14 days.
These blood pressure and palpitations have augmentin and treatment regimen very rarely reported in children. Signs and symptoms usually occur during or shortly after treatment but in some cases may not occur until several weeks after treatment has ended.
Hepatic reactions are usually reversible but they may be severe and, very rarely, deaths have been reported. Urticarial and erythematous rashes sometimes occur. Rarely erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous exfoliative dermatitis, serum sickness-like syndrome and hypersensitivity vasculitis have been reported, augmentin and treatment regimen.
Treatment should be discontinued if one of these disorders occurs. In common with other beta-lactam antibiotics angio-oedema and anaphylaxis have been reported. Interstitial nephritis can occur rarely. As with other beta-lactams transient leucopenia, thrombocytopenia and haemolytic anaemia have been reported rarely. Prolongation of bleeding time and prothrombin time has also been reported rarely see "Interactions". CNS effects have been seen very rarely, augmentin and treatment regimen.
These include reversible hyperactivity, dizziness, headache and convulsions. Convulsions may occur with impaired renal function or in those receiving high doses.
Thrombophlebitis at the site of injection has been reported occasionally. It is not suitable for intramuscular administration. Duration of therapy should be appropriate to the indication and should not exceed 14 days without review. In more serious infections, increase frequency to six-hourly intervals. The usual dose is 1. Operations where there is a high risk of infection, e. These doses are usually given at 0, augmentin and treatment regimen, 8, 16, and 24 augmentin and treatment regimen. This regimen can be continued for several days if the procedure has a significantly increased risk of infection.
Clear, clinical signs of infection at operation will require a normal course of intravenous or oral Augmentin therapy post-operatively. No change in dosage. Dialysis decreases serum concentrations of Augmentin and an additional mg IV dose may need to be given during dialysis and at the end of dialysis. Dosage in hepatic impairment: Dose with caution; monitor hepatic function at regular intervals.
There are, as yet, insufficient data on which to base a dosage recommendation. To reconstitute dissolve in 10 ml Water for Injections BP.
Augmentin Intravenous should be given by slow intravenous injection over a period of three to four augmentin and treatment regimen and used within 20 minutes of reconstitution. It may be injected directly into a vein or via a drip tube. Add, without delay, mg reconstituted solution to 50 ml infusion fluid or 1.
Infuse over 30 - 40 minutes and complete within four hours of reconstitution. For other appropriate infusion fluids, see Package Enclosure Leaflet. Any residual antibiotic solutions should be discarded. Augmentin Intravenous is less stable in infusions containing glucose, dextran or bicarbonate. Reconstituted solution should, therefore, not be diabetes and weight lifting to such infusions but may be injected into the drip tubing over a period of three to four minutes, augmentin and treatment regimen.
Problems of overdosage with co-amoxiclav are unlikely to occur. If encountered, gastro-intestinal symptoms and disturbance of the fluid and electrolyte balances may be evident. Augmentin may be removed from the circulation by haemodialysis.
Augmentin vials should be stored in a dry place below 25 o C, augmentin and treatment regimen. Augmentin is bactericidal to a wide range of organisms including: Clostridum species, Peptococcus species, Peptostreptococcus.
Effects on ability to drive and use machines: Vaginal itching, soreness and discharge may occur.